FDA approves leuprolide acetate (LA) injectable suspension for paediatric patients with central precocious puberty

Approval was based on results from single arm Phase 3 study of LA 45 mg in 64 children. The study achieved its primary endpoint, with 87% of children achieving a serum luteinizing hormone concentration of <4 IU/L at six months post injection.


Biospace Inc.